Should Integrilin be an Integral Part of Adjunctive Therapy in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction?
Status: Active, no longer recruiting
Phase of Trial: Clinical Phase Unknown
Latest Information Update: 23 Sep 2016
Price : $35 *
At a glance
- Drugs Eptifibatide (Primary)
- Indications Myocardial infarction
- Focus Therapeutic Use
- 08 Aug 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 02 Dec 2013 New trial record